Scripps Research receives $3 million anonymous donation

December 15, 2003

La Jolla, CA. December 15, 2003--The Scripps Research Institute recently received a $3 million gift to establish The Pearson Center for Alcoholism and Addiction Research that will combine biomedical research with clinical application to fight this deadly and costly disease.

The donor, who wishes to remain anonymous, stated that the gift is "in memory of my parents whom I lost to alcoholism and addiction and on behalf of other family members and friends who have suffered, directly or indirectly, from the devastating consequences of this disease. It is my hope that by generating greater public awareness and additional financial support for biomedical and clinical research, future generations of families will be spared from the devastating affects of this disease."

"We are very grateful for this extraordinary donation, " said TSRI President Richard A. Lerner, M.D. "Scripps is in a unique position to fulfill the donor's wish that biomedical research on alcoholism and addiction be translated into testing treatments to curb addiction and relapse."

In leading the center George F. Koob, Ph.D., will collaborate with Barbara Mason, Ph.D., both professors in the Department of Neuropharmacology. Koob directs the Division of Psychopharmacology and Mason directs the Division of Clinical Pharmacology.

A New Approach to Treating Alcoholism

"Alcoholism is a disease of the spirit, of behavior, and also of the brain," said Mason, who adds that the brain is often overlooked in treatment.

The traditional mode of treatment involves group therapy and other forms of psychological counseling that aim to empower the spirit and address the destructive behaviors associated with alcoholism. These are important approaches, however, the center will seek to complement them through the development of new medications to treat alcoholism--particularly drugs to help prevent relapse.

Prospects for enhancing traditional treatment through pharmaceuticals have never been more promising, and work at Scripps Research and elsewhere has already highlighted some of the key changes in the brain that occur when a person transitions from social drinking to alcohol abuse and dependence. By further researching these changes, the center's scientists hope to develop compounds that will assist in normalizing the brain during an alcoholic's recovery.

Particularly, the researchers will focus on the physiological changes in the brain that drive excessive drinking and create vulnerability to relapse. Specifically, the researchers will study the viability of utilizing new compounds, designed at Scripps Research or elsewhere, to modulate the neurological effects of alcohol and reduce excessive intake or relapse.

"Once we know the circuits and the basis for alcoholism, we can develop new targeted treatments," says Koob. "There are a number of possible neurotransmitter candidates to focus on."

One of these, called gamma amino butyric acid (GABA), is the main inhibitory neurotransmitter in the brain. Alcohol produces many of its intoxicating actions through facilitation of GABA receptor function, and preclinical studies of alcohol dependence at Scripps Research have shown that GABAergic activity decreases during alcohol withdrawal and protracted abstinence.

Another target for therapy at the center will be the brain corticotropin releasing factor (CRF) stress system-- which is responsible for activating the pituitary adrenal stress response and is one of the major neurotransmitters responsible for activating sympathetic and behavioral responses to stressors.

The CRF system seems to be central to alcoholism, and preliminary results in preclinical studies at Scripps Research have shown that compounds known as CRF antagonists can block the excessive drinking associated with alcohol withdrawal and protracted abstinence.

The center will aim to discover and test new CRF antagonists and other compounds that might be translated into new and practical treatments for alcoholism that can assist in recovery. The center will also aim to bring these compounds rapidly to clinical trials.

The center's private funding will enable the researchers themselves to determine how best to direct their efforts. The center will maximize the effectiveness of the funding by attracting additional public and private grants to conduct research on alcoholism and the brain.

Center to Build on Scripps' History of Addiction Research

The center will benefit both from Mason's experience in conducting clinical trials and Koob's expertise in neuropharmacology and preclinical research.

Since the 1970s, Koob and other Scripps Research scientists have received numerous grants and awards and are recognized for their work in the science of alcoholism, addiction, and the brain.

Scripps Research investigators identified a large part of the neurocircuitry that is involved in the reinforcing action of alcohol, and they have begun to identify how this circuitry changes when a person becomes an alcoholic. They also established several working laboratory models that mimic the transition from social drinking to dependence and that are useful for pre-clinical studies on the efficacy of a potential therapeutics.

In recent years, Koob and other researchers at Scripps have begun to collaborate with clinicians like Mason to turn some of these observations into new therapies. In fact, it was just such a collaboration between Mason and Koob that led Mason to Scripps Research in the first place. She joined the institute from the University of Miami School of Medicine in June 2003 after a successful collaboration on a research grant.

Mason has extensive experience conducting clinical trials related to alcohol addiction. In 1999, Mason and her colleagues at the University of Miami conducted a 12-week placebo-controlled clinical trial on a compound called nalmefene, which proved effective at preventing relapse to heavy drinking in alcohol-dependent individuals. Patients who received nalmefene were 2.4 times less likely to relapse to heavy drinking than those who received a placebo.

Mason was also the principal researcher on a clinical trial of a second abstinence-prolonging compound called acamprosate, which she studied with her colleagues at the University of Miami. Based on the promising results of the trial, which was conducted in 21 cities nationwide, acamprosate is in the U.S. Food and Drug Administration approval process and could become available shortly in this country.

At Scripps Research, Mason has just begun a study on gabapentin, an anti-convulsant that has been successful in controlling bipolar states, anxiety, and agitation. The compound, Mason says, may work like acamprosate to address the debilitating mood and sleep disturbances suffered by alcoholics.
About The Scripps Research Institute

The Scripps Research Institute in La Jolla, California, is one of the world's largest, private, non-profit biomedical research organizations. It stands at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. TSRI is internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, cardiovascular diseases and synthetic vaccine development.

Scripps Research Institute

Related Alcohol Articles from Brightsurf:

Alcohol use changed right after COVID-19 lockdown
One in four adults reported a change in alcohol use almost immediately after stay-at-home orders were issued: 14% reported drinking more alcohol and reported higher levels of stress and anxiety than those who did not drink and those whose use stayed the same.

Changes in hospitalizations for alcohol use disorder in US
Changes over nearly two decades in the rate of hospitalizations and in-hospital deaths from alcohol use disorder in the US were examined in this study.

Associations of alcohol consumption, alcohol-induced passing out with risk of dementia
The risk of future dementia associated with overall alcohol consumption and alcohol-induced loss of consciousness in a population of current drinkers was examined in this observational study with more than 131,000 adults.

New alcohol genes uncovered
Do you have what is known as problematic alcohol use?

Does estrogen influence alcohol use disorder?
A new study from researchers at the University of Illinois at Chicago shows that high estrogen levels may make alcohol more rewarding to female mice.

Sobering new data on drinking and driving: 15% of US alcohol-related motor vehicle fatalities involve alcohol under the legal limit
A new study in the American Journal of Preventive Medicine, published by Elsevier, found that motor vehicle crashes involving drivers with blood alcohol concentrations (BACs) below the legal limit of 0.08 percent accounted for 15% of alcohol-involved crash deaths in the United States.

Alcohol-induced deaths in US
National vital statistics data from 2000 to 2016 were used to examine how rates of alcohol-induced deaths (defined as those deaths due to alcohol consumption that could be avoided if alcohol weren't involved) have changed in the US and to compare the results by demographic groups including sex, race/ethnicity, age, socioeconomic status and geographic location.

Cuts in alcohol duty linked to 2000 more alcohol-related deaths in England
Government cuts to alcohol taxes have had dramatic consequences for public health, including nearly 2000 more alcohol-related deaths in England since 2012, according to new research from the University of Sheffield's School of Health and Related Research (ScHARR).

Integrated stepped alcohol treatment for people in HIV care improves both HIV & alcohol outcomes
Increasing the intensity of treatment for alcohol use disorder (AUD) over time improves alcohol-related outcomes among people with HIV, according to new clinical research supported by the National Institutes of Health.

The Lancet:Targets to reduce harmful alcohol use are likely to be missed as global alcohol intake increases
Increasing rates of alcohol use suggest that the world is not on track to achieve targets against harmful alcohol use, according to a study of 189 countries' alcohol intake between 1990-2017 and estimated intake up to 2030, published in The Lancet.

Read More: Alcohol News and Alcohol Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to